4-AcO-DMT

Use and effects

In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the same dose range of 10 to 20 mgorally and duration of 3 to 6hours for psilocin, psilocybin, and 4-AcO-DMT. Another publication gave a 4-AcO-DMT dose range of 10 to 15mg orally, with a typical dose of 12.5mg orally, and a duration of about 5 to 8hours. A further source gave a dose range for the drug of 5 to 30mg orally, an onset of 15 to 40minutes, and a duration of 4 to 7hours. 4-AcO-DMT is a prodrug of psilocin similarly to psilocybin and its effects are reported to be similar or identical to those of psilocybin and psilocybin-containing mushrooms. However, it is said to produce less nausea and body load than psilocybin-containing mushrooms. The drug is also often described as having a faster onset and shorter duration than psilocybin. 4-AcO-DMT is modestly less potent by weight than psilocybin in animals when they are given at equimolar doses.

Specific effects of 4-AcO-DMT have been reported to include psychedelic visuals, closed-eye imagery, synesthesia, insights, disembodiment, euphoria, feelings of bliss and unity, oceanic boundlessness, ego dissolution, sedation, cognitive impairment, and spiritual experiences, among others. Adverse effects have been reported to include psychological side effects such as anxiety, paranoia, and low mood as well as gastrointestinal side effects such as nausea and vomiting.

Contraindications

Side effects

4-AcO-DMT, as a prodrug of psilocin, is not expected to differ from psilocybin or psilocin in terms of safety.

Interactions

Pharmacology

Pharmacodynamics

4-AcO-DMT is a prodrug of psilocin (4-HO-DMT). As a prodrug of psilocin, 4-AcO-DMT acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT2A receptor. The psychedelic effects of 4-AcO-DMT are mediated specifically by activation of the serotonin 5-HT2A receptor.

Similarly to psilocybin, psilocin, and other serotonergic psychedelics, 4-AcO-DMT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In addition, like psilocybin and other psychedelics, 4-AcO-DMT fully substitutes for the psychedelic DOM in rodent drug discrimination tests. 4-AcO-DMT produces effects such as hypolocomotion and hypothermia in rodents as with psilocin as well.

Pharmacokinetics

There are no clinical studies of the pharmacokinetics of 4-AcO-DMT as of 2024. However, the pharmacokinetics of 4-AcO-DMT have been studied in rodents. The drug was confirmed to act as a prodrug of psilocin similarly to psilocybin (4-PO-DMT). However, given by intraperitoneal injection at equimolar doses, 4-AcO-DMT showed only 70% of the relative bioavailability or total exposure of psilocybin. Hence, 4-AcO-DMT results in modestly lower psilocin levels than psilocybin even when the drugs are given at equivalent doses with adjustment for differences in molecular weight. Along similar lines, the psilocin concentrations with 4-AcO-DMT 15minutes after administration were 75 to 90% of those of an equimolar dose of psilocybin. The elimination half-life of psilocin was approximately 30minutes and did not differ between 4-AcO-DMT and psilocybin. Psilocin ester prodrugs like 4-AcO-DMT are cleaved into psilocin by esterase enzymes.

A 2025 in-vitro study examined the stability and metabolism of several psilocin ester prodrugs, including 4-AcO-DMT. The results showed that 4-AcO-DMT was rapidly broken down into psilocin by esterase enzymes, with over 99.9% of the prodrug converted within 5minutes under conditions mimicking the human body (i.e., in human plasma). These findings support the idea that 4-AcO-DMT is quickly and efficiently converted into psilocin before it enters the bloodstream, and that the prodrug itself likely contributes little to the overall pharmacological effect.

Chemistry

Synthesis

4-AcO-DMT can be obtained by acetylation of psilocin under alkaline or strongly acidic conditions. It is, therefore, a synthetic compound. 4-AcO-DMT is more resistant than psilocin to oxidation under basic conditions due to its acetoxy group. It is not as difficult as psilocybin to synthesize.

Stability

Given enough time in unfavorable conditions, 4-AcO-DMT can sometimes turn into a degraded form which is brown in color and can even progress into a brown/black tar-like substance. Researchers hypothesize this is a polymerization reaction and is said to have no effect on the potency of the substance. Preliminary GCMS analysis of the closely related homologue 4-AcO-DET suggests that this degraded form of 4-AcO-DMT consists mainly of the hydroxy form of the parent molecule.

Analogues

4-AcO-DMT is closely related to psilocin (4-HO-DMT) and psilocybin (4-PO-DMT). It is a lower homologue of 4-AcO-MET, 4-AcO-DET, 4-AcO-MiPT, and 4-AcO-DiPT. Other analogues of 4-AcO-DMT include 4-AcO-DPT, 4-MeO-DMT, and 4-PrO-DMT (O-propionylpsilocin). Other related prodrugs of psilocin besides 4-AcO-DMT, 4-PrO-DMT, and psilocybin include CT-4201, EB-002, RE-109 (4-GO-DMT), and MSP-1014.

History

4-AcO-DMT and several other esters of psilocin were patented on January 16, 1963 by Sandoz via Albert Hofmann and Franz Troxler. The drug's chemical synthesis was improved by David E. Nichols and colleagues in 1999 and it was suggested as a more economical and accessible alternative to psilocybin for use in scientific research. 4-AcO-DMT was first detected as a designer drug in Europe in 2009. It became increasingly prevalent as a recreational drug in the 2010s and has been the most commonly used novel tryptamine. In the 2020s, 4-AcO-DMT became widely encountered in the form of mushroom edibles in the United States as an alternative to psilocybin and psilocybin-containing mushrooms.

Society and culture

Legal status

International

4-AcO-DMT is not scheduled under any international drug schedules, including the United Nations 1971 Convention on Psychotropic Substances, making it a potentially more accessible alternative to psilocybin for research.

Australia

4-AcO-DMT can be considered an analog of psilocin making it a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

Canada

4-AcO-DMT is not a controlled substance in Canada as of 2025.

Czech Republic

4-AcO-DMT is prohibited in Czech Republic except strictly limited research and therapeutical purposes.

Germany

4-AcO-DMT is banned in Germany according to the BtMG since it is an ester of psilocin.

Israel

4-AcO-DMT is technically illegal in Israel as of being a derivative of dimethyltryptamine (DMT).

Italy

4-AcO-DMT is illegal in Italy as it is an ester of a prohibited substance.

Sweden

The Riksdag added 4-AcO-DMT to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of January 25, 2017, published by Medical Products Agency (MPA) in regulation HSLF-FS 2017:1 listed as "4-acetoxi-N,N-dimetyltryptamin".

United Kingdom

4-AcO-DMT, being an ester of psilocin, is a Class A drug in the United Kingdom under the Misuse of Drugs Act 1971.

United States

4-AcO-DMT is not an explicitly controlled substance in the United States. However, it may be considered an analogue of psilocin and psilocybin under the Federal Analogue Act, but only if intended or used for human consumption. Conversely, if not intended for human consumption, for instance if used only for research purposes, it may be considered legal.

While not controlled at the federal level, 4-AcO-DMT is listed as a controlled substance at the state level in multiple states in the United States, including in Alabama which has made it a schedule I at the state level on March 18, 2014, along with several other tryptamine analogues.

References

References

1. (June 2022). "The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides". Psychopharmacology (Berl).
2. (October 2018). "DARK Classics in Chemical Neuroscience: Psilocybin". ACS Chem Neurosci.
3. (2024). "In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin". Front Psychiatry.
4. (1999). "Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin". Synthesis.
5. (24 June 2024). "4-AcO-DMT Is the Most Accessible (and Mysterious) Drug on the Market Right Now".
6. (January 2015). "Recent advances in the neuropsychopharmacology of serotonergic hallucinogens". Behav Brain Res.
7. (November 2022). "The neural basis of psychedelic action". Nat Neurosci.
8. (January 2020). "A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines". Human Psychopharmacology.
9. (9 August 2024). "Magic mushroom chocolates are having a moment. But do they even contain mushrooms?".
10. (4 July 2024). "Psychedelic mushroom edibles promise health benefits. Be wary, experts say.". Washington Post.
11. (18 July 2024). "Mushroom edibles are rising in popularity. It's hard to say what's in them.".
12. (4 October 2024). "Are Mushroom Edibles Safe and Legal?".
13. (5 July 2024). "What we know about microdosing candy illnesses as death investigation underway".
14. {{CiteTiHKAL https://www.erowid.org/library/books_online/tihkal/tihkal18.shtml
15. "4-AcO-DMT (Ацетилпсилоцин)".
16. (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacol Transl Sci.
17. (2018). "Behavioral Neurobiology of Psychedelic Drugs".
18. (April 2021). "Discriminative Stimulus Effects of Substituted Tryptamines in Rats". ACS Pharmacol Transl Sci.
19. (January 2024). "Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders". J Med Chem.
20. (March 2025). "Synthesis and In Vitro Profiling of Psilocin Derivatives: Improved Stability and Synthetic Properties". J Med Chem.
21. (4 July 2003). "Erowid 4-Acetoxy-DET Vaults : 4-Acetoxy-DET / Ethacetin Degradation".
22. (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacol Transl Sci.
23. "Esters of indoles".
24. {{Cite patent
25. (2024). "In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin". Front Psychiatry.
26. (30 September 2015). "Poisons Standard October 2015". Australian Government.
27. "Controlled Drugs and Substances Act".
28. "Government regulation of the list of the addictive substances". Czech Government.
29. "Anlage I BtMG".
30. "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika".
31. (1971). "[[Misuse of Drugs Act 1971]]".
32. (January 2026). "Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)". U.S. [[Department of Justice]]: [[Drug Enforcement Administration]] (DEA): Diversion Control Division.
33. (May 2020). "Prodrugs of New Psychoactive Substances (NPS): A New Challenge". J Forensic Sci.
34. (22 February 2024). "Controlled Substances List". [[Alabama Department of Public Health#State Board of Health.